Pantoloc Control

Country: European Union

Language: Bulgarian

Source: EMA (European Medicines Agency)

Buy It Now

Patient Information leaflet Patient Information leaflet (PIL)
18-01-2022
Summary of Product characteristics Summary of Product characteristics (SPC)
18-01-2022
Public Assessment Report Public Assessment Report (PAR)
18-01-2022

Active ingredient:

пантопразол

Available from:

Takeda GmbH

ATC code:

A02BC02

INN (International Name):

pantoprazole

Therapeutic group:

Инхибитори на протонната помпа

Therapeutic area:

Гастроезофагеален рефлукс

Therapeutic indications:

Краткосрочно лечение на симптомите на рефлукс (напр. киселини, киселинна регургитация) при възрастни.

Product summary:

Revision: 18

Authorization status:

Отменено

Authorization date:

2009-06-11

Patient Information leaflet

                                _ _
_ _
23
Б. ЛИСТОВКА
Лекарствен продукт с невалидно
разрешение за употреба
_ _
_ _
24
ЛИСТОВКА: ИНФОРМАЦИЯ ЗА ПОТРЕБИТЕЛЯ
PANTOLOC CONTROL 20 MG СТОМАШНО-УСТОЙЧИВИ
ТАБЛЕТКИ
пантопразол (pantoprazole)
ПРОЧЕТЕТЕ ВНИМАТЕЛНО ЦЯЛАТА ЛИСТОВКА,
ПРЕДИ ДА ЗАПОЧНЕТЕ ДА ИЗПОЛЗВАТЕ ТОВА
ЛЕКАРСТВО, ТЪЙ КАТО ТЯ СЪДЪРЖА ВАЖНА
ЗА ВАС ИНФОРМАЦИЯ.
Винаги използвайте това лекарство
точно както е описано в тази листовка
или както Ви е казал
Вашия лекар или фармацевт.
-
Запазете тази листовка. Може да имате
нужда да я прочетете отново.
-
Ако се нуждаете от допълнителна
информация или съвет, попитайте Вашия
фармацевт.
-
Ако получите някакви нежелани
лекарствени реакции, уведомете Вашия
лекар или
фармацевт. Това включва и всички
възможни нежелани реакции, неописани
в тази
листовка. Вижте точка 4.
-
Ако след 2 седмици не се чувствате
по-добре или състоянието Ви се влоши,
трябва да
потърсите лекарска помощ.
-
Вие не трябва да приемате PANTOLOC Control
повече от 4 седмици, без да се
консултирате
с лекар.
КАКВО СЪДЪРЖА ТАЗИ ЛИСТОВКА
1.
Какво представлява PANTOLOC Control и за
какво се използва
2.
Какво трябва да знаете преди да
използвате PANTOLOC Control
3.
Как да използвате PANTOLOC Control
4
                                
                                Read the complete document

Summary of Product characteristics

                                1
ПРИЛОЖЕНИЕ I
КРАТКА ХАРАКТЕРИСТИКА НА ПРОДУКТА
Лекарствен продукт с невалидно
разрешение за употреба
_ _
_ _
2
1.
ИМЕ НА ЛЕКАРСТВЕНИЯ ПРОДУКТ
PANTOLOC Control 20 mg стомашно-устойчиви
таблетки
2.
КАЧЕСТВЕН И КОЛИЧЕСТВЕН СЪСТАВ
Всяка стомашно-устойчива таблетка
съдържа 20 mg пантопразол (рantoprazole)(като
натриев
сескихидрат).
За пълния списък на помощните
вещества вижте точка 6.1.
3.
ЛЕКАРСТВЕНА ФОРМА
Стомашно-устойчиви таблетки
Жълти, елипсовидни, двойно изпъкнали,
филмирани таблетки, с отпечатан
надпис “P20” с
кафяво мастило от едната страна.
4.
КЛИНИЧНИ ДАННИ
4.1
TЕРАПЕВТИЧНИ ПОКАЗАНИЯ
PANTOLOC Control е показан за краткосрочно
лечение на симптомите на
гастро-езофагеалeн
рефлукс (като киселини в стомаха,
кисели оригвания) при възрастни.
4.2
ДОЗИРОВКА И НАЧИН НА ПРИЛОЖЕНИЕ
Дозировка
Препоръчаната доза е 20 mg пантопразол
(една таблетка) дневно.
Може да бъде необходимо таблетките да
се приемат 2-3 последователни дни за
облекчаване на
симптомите. При настъпване на пълно
повлияване на симптомите, лечението
трябва да се
прекрати.
Лечението не трябва да продължи
повече от 4 седмици, без консултация с
лекар.
Ако не се постигне облекчаване на
си
                                
                                Read the complete document

Similar products

Active ingredient пантопразол

пантопразол

ATC code A02BC02

A02BC02

Marketed by Takeda GmbH

Takeda GmbH

INN (International Name) pantoprazole

pantoprazole

Documents in other languages

Patient Information leaflet Patient Information leaflet Spanish 18-01-2022
Summary of Product characteristics Summary of Product characteristics Spanish 18-01-2022
Public Assessment Report Public Assessment Report Spanish 18-01-2022
Patient Information leaflet Patient Information leaflet Czech 18-01-2022
Summary of Product characteristics Summary of Product characteristics Czech 18-01-2022
Public Assessment Report Public Assessment Report Czech 18-01-2022
Patient Information leaflet Patient Information leaflet Danish 18-01-2022
Summary of Product characteristics Summary of Product characteristics Danish 18-01-2022
Public Assessment Report Public Assessment Report Danish 18-01-2022
Patient Information leaflet Patient Information leaflet German 18-01-2022
Summary of Product characteristics Summary of Product characteristics German 18-01-2022
Public Assessment Report Public Assessment Report German 18-01-2022
Patient Information leaflet Patient Information leaflet Estonian 18-01-2022
Summary of Product characteristics Summary of Product characteristics Estonian 18-01-2022
Public Assessment Report Public Assessment Report Estonian 18-01-2022
Patient Information leaflet Patient Information leaflet Greek 18-01-2022
Summary of Product characteristics Summary of Product characteristics Greek 18-01-2022
Public Assessment Report Public Assessment Report Greek 18-01-2022
Patient Information leaflet Patient Information leaflet English 18-01-2022
Summary of Product characteristics Summary of Product characteristics English 18-01-2022
Public Assessment Report Public Assessment Report English 18-01-2022
Patient Information leaflet Patient Information leaflet French 18-01-2022
Summary of Product characteristics Summary of Product characteristics French 18-01-2022
Public Assessment Report Public Assessment Report French 18-01-2022
Patient Information leaflet Patient Information leaflet Italian 18-01-2022
Summary of Product characteristics Summary of Product characteristics Italian 18-01-2022
Public Assessment Report Public Assessment Report Italian 18-01-2022
Patient Information leaflet Patient Information leaflet Latvian 18-01-2022
Summary of Product characteristics Summary of Product characteristics Latvian 18-01-2022
Public Assessment Report Public Assessment Report Latvian 18-01-2022
Patient Information leaflet Patient Information leaflet Lithuanian 18-01-2022
Summary of Product characteristics Summary of Product characteristics Lithuanian 18-01-2022
Public Assessment Report Public Assessment Report Lithuanian 18-01-2022
Patient Information leaflet Patient Information leaflet Hungarian 18-01-2022
Summary of Product characteristics Summary of Product characteristics Hungarian 18-01-2022
Public Assessment Report Public Assessment Report Hungarian 18-01-2022
Patient Information leaflet Patient Information leaflet Maltese 18-01-2022
Summary of Product characteristics Summary of Product characteristics Maltese 18-01-2022
Public Assessment Report Public Assessment Report Maltese 18-01-2022
Patient Information leaflet Patient Information leaflet Dutch 18-01-2022
Summary of Product characteristics Summary of Product characteristics Dutch 18-01-2022
Public Assessment Report Public Assessment Report Dutch 18-01-2022
Patient Information leaflet Patient Information leaflet Polish 18-01-2022
Summary of Product characteristics Summary of Product characteristics Polish 18-01-2022
Public Assessment Report Public Assessment Report Polish 18-01-2022
Patient Information leaflet Patient Information leaflet Portuguese 18-01-2022
Summary of Product characteristics Summary of Product characteristics Portuguese 18-01-2022
Public Assessment Report Public Assessment Report Portuguese 18-01-2022
Patient Information leaflet Patient Information leaflet Romanian 18-01-2022
Summary of Product characteristics Summary of Product characteristics Romanian 18-01-2022
Public Assessment Report Public Assessment Report Romanian 18-01-2022
Patient Information leaflet Patient Information leaflet Slovak 18-01-2022
Summary of Product characteristics Summary of Product characteristics Slovak 18-01-2022
Public Assessment Report Public Assessment Report Slovak 18-01-2022
Patient Information leaflet Patient Information leaflet Slovenian 18-01-2022
Summary of Product characteristics Summary of Product characteristics Slovenian 18-01-2022
Public Assessment Report Public Assessment Report Slovenian 18-01-2022
Patient Information leaflet Patient Information leaflet Finnish 18-01-2022
Summary of Product characteristics Summary of Product characteristics Finnish 18-01-2022
Public Assessment Report Public Assessment Report Finnish 18-01-2022
Patient Information leaflet Patient Information leaflet Swedish 18-01-2022
Summary of Product characteristics Summary of Product characteristics Swedish 18-01-2022
Public Assessment Report Public Assessment Report Swedish 18-01-2022
Patient Information leaflet Patient Information leaflet Norwegian 18-01-2022
Summary of Product characteristics Summary of Product characteristics Norwegian 18-01-2022
Patient Information leaflet Patient Information leaflet Icelandic 18-01-2022
Summary of Product characteristics Summary of Product characteristics Icelandic 18-01-2022
Patient Information leaflet Patient Information leaflet Croatian 18-01-2022
Summary of Product characteristics Summary of Product characteristics Croatian 18-01-2022

Search alerts related to this product

Alerts Pantoloc Control пантопразол pantoprazole

Pantoloc Control пантопразол pantoprazole

View documents history

Documents history Documents history

Pantoloc Control